-
1 Comment
Sunesis Pharmaceuticals, Inc is currently in a long term uptrend where the price is trading 55.3% above its 200 day moving average.
From a valuation standpoint, the stock is 97.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 30.0.
Sunesis Pharmaceuticals, Inc's total revenue sank by 100.0% to $0 since the same quarter in the previous year.
Its net income has increased by 9.1% to $-5M since the same quarter in the previous year.
Finally, its free cash flow fell by 51.1% to $-6M since the same quarter in the previous year.
Based on the above factors, Sunesis Pharmaceuticals, Inc gets an overall score of 3/5.
| Industry | Biotechnology |
|---|---|
| Sector | Healthcare |
| ISIN | US8673288747 |
| CurrencyCode | USD |
| Exchange | NASDAQ |
| Beta | 2.23 |
|---|---|
| Market Cap | 96M |
| Target Price | 21.58 |
| PE Ratio | None |
| Dividend Yield | 0.0% |
As of February 24, 2021, Sunesis Pharmaceuticals, Inc. was acquired by Viracta Therapeutics, Inc., in a reverse merger transaction. Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of hematologic and solid cancers. Its lead product candidate is vecabrutinib, a non-covalent inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and other B-cell malignancies. The company is also developing SNS-510, which is in preclinical pharmacology studies for the treatment of solid tumor and hematologic malignancies; various other partnered programs, such as TAK-580, a pan-Raf inhibitor program that is in Phase 1 clinical trial for the treatment of pediatric low-grade glioma; and vosaroxin, an anti-cancer quinolone derivative that intercalates DNA and inhibits topoisomerase II. It has a collaboration agreement with Biogen Idec MA, Inc. to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of PDK1. Sunesis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for SNSS using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
